早期乳腺癌患者21基因复发评分与局部复发的关系

IF 1.9
Yufei Zeng, Weiqi Gao, Xiaosong Chen, Kunwei Shen
{"title":"早期乳腺癌患者21基因复发评分与局部复发的关系","authors":"Yufei Zeng,&nbsp;Weiqi Gao,&nbsp;Xiaosong Chen,&nbsp;Kunwei Shen","doi":"10.3233/CBM-210274","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The 21-gene recurrence score (RS) assay has been validated to predict the risk of disease-free survival in estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer patients. However, its relation with locoregional recurrence (LRR) risk is unclear.</p><p><strong>Objective: </strong>This study aimed to explore the ability of RS to predict LRR risk.</p><p><strong>Methods: </strong>Consecutive ER-positive, HER2-negative, pT1, pN0-1, and M0 early breast cancer patients were analyzed retrospectively. According to RS, patients were divided into low- (RS < 18), intermediate- (RS 18-30), and high-risk (RS ⩾ 31) groups. The primary endpoint was LRR. Subgroup analysis was conducted according to different nodal statuses and surgery types.</p><p><strong>Results: </strong>A total of 1558 patients were enrolled: 354 (22.7%), 788 (50.6%), and 416 (26.7%) patients in the low-, intermediate-, and high-risk groups, respectively. The median follow-up time was 53 months, and 2, 8, and 14 LRR events were observed in the low-, intermediate-, and high-risk groups, respectively (P= 0.004). Both univariate (P= 0.009) and multivariate (P= 0.010) analyses demonstrated that 21-gene RS was correlated with LRR. Compared to low-risk patients, high-risk patients were at greater risk of LRR (HR 5.75, 95% CI 1.30-25.31, P= 0.021). Among pN0 (P= 0.033), pN1 (P= 0.049) and postmastectomy patients (P= 0.012), 21-gene RS remained predictive of the risk of LRR.</p><p><strong>Conclusion: </strong>The 21-gene RS assay was significantly associated with the risk of LRR in ER-positive, HER2-negative early breast cancer patients. Among patients with different nodal statuses and patients receiving mastectomy, RS remained predictive of the risk of LRR.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":" ","pages":"111-118"},"PeriodicalIF":1.9000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Association of 21-gene recurrence score and locoregional recurrence in early breast cancer patients.\",\"authors\":\"Yufei Zeng,&nbsp;Weiqi Gao,&nbsp;Xiaosong Chen,&nbsp;Kunwei Shen\",\"doi\":\"10.3233/CBM-210274\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The 21-gene recurrence score (RS) assay has been validated to predict the risk of disease-free survival in estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer patients. However, its relation with locoregional recurrence (LRR) risk is unclear.</p><p><strong>Objective: </strong>This study aimed to explore the ability of RS to predict LRR risk.</p><p><strong>Methods: </strong>Consecutive ER-positive, HER2-negative, pT1, pN0-1, and M0 early breast cancer patients were analyzed retrospectively. According to RS, patients were divided into low- (RS < 18), intermediate- (RS 18-30), and high-risk (RS ⩾ 31) groups. The primary endpoint was LRR. Subgroup analysis was conducted according to different nodal statuses and surgery types.</p><p><strong>Results: </strong>A total of 1558 patients were enrolled: 354 (22.7%), 788 (50.6%), and 416 (26.7%) patients in the low-, intermediate-, and high-risk groups, respectively. The median follow-up time was 53 months, and 2, 8, and 14 LRR events were observed in the low-, intermediate-, and high-risk groups, respectively (P= 0.004). Both univariate (P= 0.009) and multivariate (P= 0.010) analyses demonstrated that 21-gene RS was correlated with LRR. Compared to low-risk patients, high-risk patients were at greater risk of LRR (HR 5.75, 95% CI 1.30-25.31, P= 0.021). Among pN0 (P= 0.033), pN1 (P= 0.049) and postmastectomy patients (P= 0.012), 21-gene RS remained predictive of the risk of LRR.</p><p><strong>Conclusion: </strong>The 21-gene RS assay was significantly associated with the risk of LRR in ER-positive, HER2-negative early breast cancer patients. Among patients with different nodal statuses and patients receiving mastectomy, RS remained predictive of the risk of LRR.</p>\",\"PeriodicalId\":520578,\"journal\":{\"name\":\"Cancer biomarkers : section A of Disease markers\",\"volume\":\" \",\"pages\":\"111-118\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer biomarkers : section A of Disease markers\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3233/CBM-210274\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer biomarkers : section A of Disease markers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3233/CBM-210274","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

背景:21基因复发评分(RS)测定已被证实可预测雌激素受体(ER)阳性、人表皮生长因子受体2 (HER2)阴性的早期乳腺癌患者的无病生存风险。然而,其与局部复发(LRR)风险的关系尚不清楚。目的:探讨RS对LRR风险的预测能力。方法:回顾性分析连续er阳性、her2阴性、pT1、pN0-1、M0早期乳腺癌患者。根据RS,患者被分为低(RS < 18)、中(RS 18-30)和高风险(RS大于或等于31)组。主要终点为LRR。根据不同淋巴结状态及手术类型进行亚组分析。结果:共纳入1558例患者:低、中、高风险组分别为354例(22.7%)、788例(50.6%)和416例(26.7%)。中位随访时间为53个月,低、中、高风险组LRR事件发生率分别为2例、8例、14例(P= 0.004)。单因素分析(P= 0.009)和多因素分析(P= 0.010)均显示21基因RS与LRR相关。与低危患者相比,高危患者LRR风险更高(HR 5.75, 95% CI 1.30-25.31, P= 0.021)。在pN0 (P= 0.033)、pN1 (P= 0.049)和乳房切除术后患者(P= 0.012)中,21基因RS仍可预测LRR风险。结论:在er阳性、her2阴性的早期乳腺癌患者中,21基因RS检测与LRR发生风险显著相关。在不同淋巴结状态的患者和接受乳房切除术的患者中,RS仍然可以预测LRR的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Association of 21-gene recurrence score and locoregional recurrence in early breast cancer patients.

Background: The 21-gene recurrence score (RS) assay has been validated to predict the risk of disease-free survival in estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer patients. However, its relation with locoregional recurrence (LRR) risk is unclear.

Objective: This study aimed to explore the ability of RS to predict LRR risk.

Methods: Consecutive ER-positive, HER2-negative, pT1, pN0-1, and M0 early breast cancer patients were analyzed retrospectively. According to RS, patients were divided into low- (RS < 18), intermediate- (RS 18-30), and high-risk (RS ⩾ 31) groups. The primary endpoint was LRR. Subgroup analysis was conducted according to different nodal statuses and surgery types.

Results: A total of 1558 patients were enrolled: 354 (22.7%), 788 (50.6%), and 416 (26.7%) patients in the low-, intermediate-, and high-risk groups, respectively. The median follow-up time was 53 months, and 2, 8, and 14 LRR events were observed in the low-, intermediate-, and high-risk groups, respectively (P= 0.004). Both univariate (P= 0.009) and multivariate (P= 0.010) analyses demonstrated that 21-gene RS was correlated with LRR. Compared to low-risk patients, high-risk patients were at greater risk of LRR (HR 5.75, 95% CI 1.30-25.31, P= 0.021). Among pN0 (P= 0.033), pN1 (P= 0.049) and postmastectomy patients (P= 0.012), 21-gene RS remained predictive of the risk of LRR.

Conclusion: The 21-gene RS assay was significantly associated with the risk of LRR in ER-positive, HER2-negative early breast cancer patients. Among patients with different nodal statuses and patients receiving mastectomy, RS remained predictive of the risk of LRR.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信